Musculoskeletal complications in patients with diabetes mellitus

1. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels (BE): International Diabetes Federation, 2019. 2. Jung CH, Son JW, Kang S, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J 2021;45:1–10.
crossref pmid pmc pdf
3. Oh SH, Ku H, Park KS. Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data. BMC Public Health 2021;21:548.
crossref pmid pmc pdf
4. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia 2019;62:3–16.
crossref pmid pdf
5. Pandey A, Usman K, Reddy H, Gutch M, Jain N, Qidwai S. Prevalence of hand disorders in type 2 diabetes mellitus and its correlation with microvascular complications. Ann Med Health Sci Res 2013;3:349–354.
crossref pmid pmc
6. Adriaanse MC, Drewes HW, van der Heide I, Struijs JN, Baan CA. The impact of comorbid chronic conditions on quality of life in type 2 diabetes patients. Qual Life Res 2016;25:175–182.
crossref pmid pmc pdf
7. Monnier VM, Sell DR, Gao X, et al. Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC. BMJ Open Diabetes Res Care 2022;10:e002667.
crossref pmid pmc
8. Khalid M, Petroianu G, Adem A. Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules 2022;12:542.
crossref pmid pmc
9. Holte KB, Juel NG, Brox JI, et al. Hand, shoulder and back stiffness in long-term type 1 diabetes; cross-sectional association with skin collagen advanced glycation end-products: the Dialong study. J Diabetes Complications 2017;31:1408–1414.
crossref pmid
10. Avery NC, Bailey AJ. The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol (Paris) 2006;54:387–395.
crossref pmid
11. Boivin GP, Elenes EY, Schultze AK, Chodavarapu H, Hunter SA, Elased KM. Biomechanical properties and histology of db/db diabetic mouse Achilles tendon. Muscles Ligaments Tendons J 2014;4:280–284.
crossref pmid pmc
12. Reddy GK, Stehno-Bittel L, Enwemeka CS. Glycation-induced matrix stability in the rabbit Achilles tendon. Arch Biochem Biophys 2002;399:174–180.
crossref pmid
13. Reddy GK. Cross-linking in collagen by nonenzymatic glycation increases the matrix stiffness in rabbit Achilles tendon. Exp Diabesity Res 2004;5:143–153.
crossref pmid pmc pdf
14. Valencia JV, Weldon SC, Quinn D, et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 2004;324:68–78.
crossref pmid
15. Franke S, Sommer M, Ruster C, et al. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther 2009;11:R136.
crossref pmid pmc
16. Handa A, Gotoh M, Hamada K, et al. Vascular endothelial growth factor 121 and 165 in the subacromial bursa are involved in shoulder joint contracture in type II diabetics with rotator cuff disease. J Orthop Res 2003;21:1138–1144.
crossref pmid
17. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–1625.
pmid
18. Larkin ME, Barnie A, Braffett BH, et al. Musculoskeletal complications in type 1 diabetes. Diabetes Care 2014;37:1863–1869.
crossref pmid pmc pdf
19. Arkkila PE, Kantola IM, Viikari JS. Limited joint mobility in non-insulin-dependent diabetic (NIDDM) patients: correlation to control of diabetes, atherosclerotic vascular disease, and other diabetic complications. J Diabetes Complications 1997;11:208–217.
crossref pmid
20. Silverstein JH, Gordon G, Pollock BH, Rosenbloom AL. Longterm glycemic control influences the onset of limited joint mobility in type 1 diabetes. J Pediatr 1998;132:944–947.
crossref pmid
21. Kapoor A, Sibbitt WL Jr. Contractures in diabetes mellitus: the syndrome of limited joint mobility. Semin Arthritis Rheum 1989;18:168–180.
crossref pmid
22. Lundbaek K. Stiff hands in long-term diabetes. Acta Med Scand 1957;158:447–451.
crossref pmid
23. Sozen T, Basaran NC, Tinazli M, Ozisik L. Musculoskeletal problems in diabetes mellitus. Eur J Rheumatol 2018;5:258–265.
crossref pmid pmc
24. Gerrits EG, Landman GW, Nijenhuis-Rosien L, Bilo HJ. Limited joint mobility syndrome in diabetes mellitus: a minireview. World J Diabetes 2015;6:1108–1112.
crossref pmid pmc
25. Hill NE, Roscoe D, Stacey MJ, Chew S. Cheiroarthropathy and tendinopathy in diabetes. Diabet Med 2019;36:939–947.
crossref pmid pdf
26. Al-Homood IA. Rheumatic conditions in patients with diabetes mellitus. Clin Rheumatol 2013;32:527–533.
crossref pmid pdf
27. Lopez-Martin I, Benito Ortiz L, Rodriguez-Borlado B, Cano Langreo M, Garcia-Martinez FJ, Martin Rodriguez MF. Association between limited joint mobility syndrome and risk of accidental falls in diabetic patients. Semergen 2015;41:70–75.
pmid
28. Zimny S, Schatz H, Pfohl M. The role of limited joint mobility in diabetic patients with an at-risk foot. Diabetes Care 2004;27:942–946.
crossref pmid pdf
29. Francia P, Gulisano M, Anichini R, Seghieri G. Diabetic foot and exercise therapy: step by step the role of rigid posture and biomechanics treatment. Curr Diabetes Rev 2014;10:86–99.
crossref pmid pmc
30. Abate M, Schiavone C, Salini V, Andia I. Management of limited joint mobility in diabetic patients. Diabetes Metab Syndr Obes 2013;6:197–207.
crossref pmid pmc
31. Olney RK. Carpal tunnel syndrome: complex issues with a “simple” condition. Neurology 2001;56:1431–1432.
crossref pmid
32. Atroshi I, Gummesson C, Johnsson R, Ornstein E, Ranstam J, Rosen I. Prevalence of carpal tunnel syndrome in a general population. JAMA 1999;282:153–158.
crossref pmid
33. Perkins BA, Olaleye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care 2002;25:565–569.
crossref pmid pdf
34. Pourmemari MH, Shiri R. Diabetes as a risk factor for carpal tunnel syndrome: a systematic review and meta-analysis. Diabet Med 2016;33:10–16.
crossref pmid
35. Rydberg M, Zimmerman M, Gottsater A, Svensson AM, Eeg-Olofsson K, Dahlin LB. Diabetic hand: prevalence and incidence of diabetic hand problems using data from 1.1 million inhabitants in southern Sweden. BMJ Open Diabetes Res Care 2022;10:e002614.
crossref pmid pmc
36. Padua L, Coraci D, Erra C, et al. Carpal tunnel syndrome: clinical features, diagnosis, and management. Lancet Neurol 2016;15:1273–1284.
crossref pmid
37. Atroshi I, Flondell M, Hofer M, Ranstam J. Methylprednisolone injections for the carpal tunnel syndrome: a randomized, placebo-controlled trial. Ann Intern Med 2013;159:309–317.
crossref pmid
38. Shi Q, MacDermid JC. Is surgical intervention more effective than non-surgical treatment for carpal tunnel syndrome?: a systematic review. J Orthop Surg Res 2011;6:17.
crossref pmid pmc
39. Makepeace A, Davis WA, Bruce DG, Davis TM. Incidence and determinants of carpal tunnel decompression surgery in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2008;31:498–500.
pmid
41. Blyth MJ, Ross DJ. Diabetes and trigger finger. J Hand Surg Br 1996;21:244–245.
crossref pmid pdf
42. Vance MC, Tucker JJ, Harness NG. The association of hemoglobin A1c with the prevalence of stenosing flexor tenosynovitis. J Hand Surg Am 2012;37:1765–1769.
crossref pmid
43. Fitzgibbons PG, Weiss AP. Hand manifestations of diabetes mellitus. J Hand Surg Am 2008;33:771–775.
crossref pmid
44. Ferrara PE, Codazza S, Maccauro G, Zirio G, Ferriero G, Ronconi G. Physical therapies for the conservative treatment of the trigger finger: a narrative review. Orthop Rev (Pavia) 2020;12(Suppl 1):8680.
crossref pmid pmc pdf
45. Kuczmarski AS, Harris AP, Gil JA, Weiss AC. Management of diabetic trigger finger. J Hand Surg Am 2019;44:150–153.
crossref pmid
46. Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren’s disease. J Bone Joint Surg Br 1984;66:322–325.
crossref pmid pdf
47. Hart MG, Hooper G. Clinical associations of Dupuytren’s disease. Postgrad Med J 2005;81:425–428.
crossref pmid pmc
48. Trojian TH, Chu SM. Dupuytren’s disease: diagnosis and treatment. Am Fam Physician 2007;76:86–89.
pmid
49. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 2009;361:968–979.
crossref pmid
50. Norotte G, Apoil A, Travers V. A ten years follow-up of the results of surgery for Dupuytren’s disease: a study of fifty-eight cases. Ann Chir Main 1988;7:277–281.
pmid
52. Baslund B, Thomsen BS, Jensen EM. Frozen shoulder: current concepts. Scand J Rheumatol 1990;19:321–325.
crossref pmid
53. Balci N, Balci MK, Tuzuner S. Shoulder adhesive capsulitis and shoulder range of motion in type II diabetes mellitus: association with diabetic complications. J Diabetes Complications 1999;13:135–140.
pmid
54. Huang YP, Fann CY, Chiu YH, et al. Association of diabetes mellitus with the risk of developing adhesive capsulitis of the shoulder: a longitudinal population-based follow up study. Arthritis Care Res (Hoboken) 2013;65:1197–1202.
crossref pmid
55. Gundtoft PH, Attrup ML, Kristensen AK, Vobbe JW, Sorensen L, Holmich P. Diabetes mellitus affects the prognosis of frozen shoulder. Dan Med J 2020;67:A02200071.
pmid
56. Lewis J. Frozen shoulder contracture syndrome: aetiology, diagnosis and management. Man Ther 2015;20:2–9.
crossref pmid
57. Whelton C, Peach CA. Review of diabetic frozen shoulder. Eur J Orthop Surg Traumatol 2018;28:363–371.
crossref pmid pdf
58. Titchener AG, White JJ, Hinchliffe SR, Tambe AA, Hubbard RB, Clark DI. Comorbidities in rotator cuff disease: a case-control study. J Shoulder Elbow Surg 2014;23:1282–1288.
crossref pmid
59. Lin TT, Lin CH, Chang CL, Chi CH, Chang ST, Sheu WH. The effect of diabetes, hyperlipidemia, and statins on the development of rotator cuff disease: a nationwide, 11-year, longitudinal, population-based follow-up study. Am J Sports Med 2015;43:2126–2132.
crossref pmid pdf
60. Chi AS, Kim J, Long SS, Morrison WB, Zoga AC. Non-contrast MRI diagnosis of adhesive capsulitis of the shoulder. Clin Imaging 2017;44:46–50.
crossref pmid
61. Robinson CM, Seah KT, Chee YH, Hindle P, Murray IR. Frozen shoulder. J Bone Joint Surg Br 2012;94:1–9.
crossref pdf
62. Cho JH. Updates on the treatment of adhesive capsulitis with hydraulic distension. Yeungnam Univ J Med 2021;38:19–26.
crossref pmid pmc pdf
63. Edmonds ME. Progress in care of the diabetic foot. Lancet 1999;354:270–272.
crossref pmid
64. Charcot M. Demonstration of arthropathic affections of locomotor ataxy. Br Med J 1881;2:285.
crossref pmid pmc
65. Trieb K. The Charcot foot: pathophysiology, diagnosis and classification. Bone Joint J 2016;98-B:1155–1159.
pmid
66. Schoots IG, Slim FJ, Busch-Westbroek TE, Maas M. Neuro-osteoarthropathy of the foot-radiologist: friend or foe? Semin Musculoskelet Radiol 2010;14:365–376.
crossref pmid
67. Marmolejo VS, Arnold JF, Ponticello M, Anderson CA. Charcot foot: clinical clues, diagnostic strategies, and treatment principles. Am Fam Physician 2018;97:594–599.
pmid
68. Rosenbaum AJ, DiPreta JA. Classifications in brief: Eichenholtz classification of Charcot arthropathy. Clin Orthop Relat Res 2015;473:1168–1171.
crossref pmid pmc
69. Schmidt BM, Holmes CM. Updates on diabetic foot and Charcot osteopathic arthropathy. Curr Diab Rep 2018;18:74.
crossref pmid pdf
70. Guven MF, Karabiber A, Kaynak G, Ogut T. Conservative and surgical treatment of the chronic Charcot foot and ankle. Diabet Foot Ankle 2013;Aug. 2. 4:21177.
crossref pmid pmc
71. Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Rep 2014;16:400.
crossref pmid pmc pdf
72. Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994;78:25–29.
crossref pmid
73. Liu Q, Gamble G, Pickering K, Morton S, Dalbeth N. Prevalence and clinical factors associated with gout in patients with diabetes and prediabetes. Rheumatology (Oxford) 2012;51:757–759.
crossref pmid
74. Pan A, Teng GG, Yuan JM, Koh WP. Bidirectional association between diabetes and gout: the Singapore Chinese Health Study. Sci Rep 2016;6:25766.
crossref pmid pmc pdf
75. Lai HM, Chen CJ, Su BY, et al. Gout and type 2 diabetes have a mutual inter-dependent effect on genetic risk factors and higher incidences. Rheumatology (Oxford) 2012;51:715–720.
crossref pmid
76. Engel B, Just J, Bleckwenn M, Weckbecker K. Treatment options for gout. Dtsch Arztebl Int 2017;114:215–222.
crossref pmid pmc
77. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–795.
crossref pmid
78. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int 2007;18:427–444.
crossref pmid pdf
79. Thong EP, Herath M, Weber DR, et al. Fracture risk in young and middle-aged adults with type 1 diabetes mellitus: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2018;89:314–323.
crossref pmid pmc pdf
80. Ni Y, Fan D. Diabetes mellitus is a risk factor for low bone mass-related fractures: a meta-analysis of cohort studies. Medicine (Baltimore) 2017;96:e8811.
pmid pmc
81. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404–3410.
crossref pmid
82. Schwartz AV, Margolis KL, Sellmeyer DE, et al. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care 2012;35:1525–1531.
crossref pmid pmc pdf
83. Li CI, Liu CS, Lin WY, et al. Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes: a competing risk analysis of Taiwan Diabetes Cohort Study. J Bone Miner Res 2015;30:1338–1346.
crossref pmid
84. Oei L, Zillikens MC, Dehghan A, et al. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. Diabetes Care 2013;36:1619–1628.
pmid pmc
85. Moayeri A, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag 2017;13:455–468.
crossref pmid pmc pdf
86. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009;84:45–55.
crossref pmid pdf
87. Hough FS, Pierroz DD, Cooper C, Ferrari SL, IOF CSA Bone and Diabetes Working Group. Mechanisms in endocrinology: mechanisms and evaluation of bone fragility in type 1 diabetes mellitus. Eur J Endocrinol 2016;174:R127–R138.
crossref pmid
88. Napoli N, Chandran M, Pierroz DD, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 2017;13:208–219.
crossref pmid pdf
89. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002;25:1749–1754.
pmid
90. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32–39.
crossref pmid pmc
91. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157–166.
crossref pmid pmc
92. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357.
crossref pmid
93. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128.
crossref pmid
94. Cheng L, Li YY, Hu W, et al. Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diabetes Metab 2019;45:436–445.
crossref pmid
95. Ferrari SL, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int 2018;29:2585–2596.
crossref pmid pmc pdf
96. Utsinger PD. Diffuse idiopathic skeletal hyperostosis. Clin Rheum Dis 1985;11:325–351.
crossref pmid
97. Pillai S, Littlejohn G. Metabolic factors in diffuse idiopathic skeletal hyperostosis: a review of clinical data. Open Rheumatol J 2014;8:116–128.
crossref pmid pmc pdf
98. Vaishya R, Vijay V, Nwagbara IC, Agarwal AK. Diffuse idiopathic skeletal hyperostosis (DISH): a common but less known cause of back pain. J Clin Orthop Trauma 2017;8:191–196.
crossref pmid pmc
99. Angelopoulou F, Kraniotis P, Daoussis D. DISH vs spondyloar-thritides. Mediterr J Rheumatol 2020;31:81–83.
crossref pmid pmc
100. Mader R, Verlaan JJ, Eshed I, et al. Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. RMD Open 2017;3:e000472.
crossref

留言 (0)

沒有登入
gif